News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK)'s Ditching of Aranesp Biosimilar Highlights Follow-on-Biologics Pitfalls


5/24/2010 9:11:48 PM

Seeking Alpha -- The developmental and regulatory minefield confronting companies attempting to develop follow-on-biologics (FOBs), or biosimilars, was highlighted again this week with Merck's (MRK) decision to scrap development of MK-2578, its pegylated form of erythropoietin similar to Amgen’s (AMGN) blockbuster anaemia drug Aranesp.

Read at Seeking Alpha

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES